Cipla has been awarded $188.95 million of Global Fund ARV Tender. The company has been selected as a ‘Panel Supplier’ for a Supplier Partnership Agreement. The contract is effective from the first of January 2015 and will run for a period of three years. The supplies will begin from Q4 FY 2015.
The company has a long-term association with Global Fund since 2002. Last year, Cipla has been one of the suppliers who has been awarded with a long-term contract for supplying anti-malarial drugs. The anti-retrovirals drugs will be manufactured in Cipla’s state-of-the-art manufacturing facilities in India, which has been approved by various international regulatory agencies.
Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1508.40 |
Dr. Reddys Lab | 6332.85 |
Cipla | 1424.40 |
Zydus Lifesciences | 992.00 |
Lupin | 1663.00 |
View more.. |